Snake venom disintegrins: evolution of structure and function.
Snake venom disintegrins: novel dimeric disintegrins and structural diversification by disulphide bond engineering.
- J. Calvete, M. Moreno‐Murciano, R. Theakston, D. Kisiel, C. Marcinkiewicz
- BiologyBiochemical Journal
- 15 June 2003
Comparison of the amino acid sequences of the dimeric disintegrins with those of other disintegr Ins supports the view that the different disintegrin subfamilies evolved from a common ADAM (a disintegrin and metalloproteinase-like) scaffold and that structural diversification occurred through disulphide bond engineering.
Viper Venom Disintegrins and Related Molecules
- M. McLane, C. Marcinkiewicz, S. Vijay-Kumar, I. Wierzbicka-Patynowski, S. Niewiarowski
- BiologyProceedings of the Society for Experimental…
- 1 November 1998
This review is to discuss the literature and the authors'own data on the structure and function of disintegrins and their relevance to the studies on proteins containing disintegrin-like domains, such as hemorrhagins and ADAMs.
Obtustatin A Potent Selective Inhibitor of α1β1 Integrin in Vitro and Angiogenesis in Vivo
Otustatin potently inhibited angiogenesis in vivo in the chicken chorioallantoic membrane assay, and in the Lewis lung syngeneic mouse model, it reduced tumor development by half, confirming and extending previous results on the relevance of α1β1 integrin to ang iogenesis and suggesting novel approaches to the generation ofAngiogenesis inhibitors.
Compression stiffening of brain and its effect on mechanosensing by glioma cells
It is suggested that local tissue stiffness has the potential to alter glial cell function, and that stiffness changes in brain tumors might arise not from increased deposition or crosslinking of the collagen-rich extracellular matrix, but from pressure gradients that form within the tumors in vivo.
Integrins in pulmonary inflammatory diseases.
- S. Bazan-Socha, A. Bukiej, C. Marcinkiewicz, J. Musial
- Biology, MedicineCurrent pharmaceutical design
- 28 February 2005
Agents that could inhibit the function of one or more of these integrins could provide a novel therapeutic strategy targeted to inhibit inflammatory and immune phenomena in the lung.
Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug…
Development of selective drugs specific for the trkA and VEGFR-2 subtypes of receptors will provide new tools for the treatment of neurodegenerative diseases, as well as of numerous angiogenesis-dependent diseases, such as cancer, diabetes, and arthritis.
Non-RGD-containing snake venom disintegrins, functional and structural relations.
Identification of Novel β1 Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1*
β1 integrins mediate cell adhesion to the type 1 and type 2 repeats of thrombospondin-1, and data suggest that some biological activities of A4.1 result from antagonism of these novel β1 integrin binding sites.
Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo.
Otustatin potently inhibited angiogenesis in vivo in the chicken chorioallantoic membrane assay, and in the Lewis lung syngeneic mouse model, it reduced tumor development by half, confirming and extending previous results on the relevance of alpha1beta1 integrin to ang iogenesis and suggesting novel approaches to the generation of angiogenic inhibitors.